Arcellx (ACLX) Competitors

Arcellx (NASDAQ:ACLX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.

Do analysts rate ACLX or GMAB?

Arcellx currently has a consensus target price of $78.00, indicating a potential downside of 0.29%. Genmab A/S has a consensus target price of $45.20, indicating a potential upside of 92.42%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcellx	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07
Genmab A/S	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

Which has better valuation & earnings, ACLX or GMAB?

Genmab A/S has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcellx	$144.75M	28.92	-$70.69M	-$1.03	-75.95
Genmab A/S	$19.02B	0.82	$631.91M	$1.20	19.58

Is ACLX or GMAB more profitable?

Genmab A/S has a net margin of 29.06% compared to Arcellx's net margin of -37.23%. Genmab A/S's return on equity of 17.48% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcellx	-37.23%	-12.42%	-7.30%
Genmab A/S	29.06%	17.48%	15.13%

Do institutionals & insiders hold more shares of ACLX or GMAB?

96.0% of Arcellx shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 6.2% of Arcellx shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer ACLX or GMAB?

Genmab A/S received 105 more outperform votes than Arcellx when rated by MarketBeat users. However, 78.79% of users gave Arcellx an outperform vote while only 62.30% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Arcellx	Outperform Votes 52 78.79%	Underperform Votes 14 21.21%
Genmab A/S	Outperform Votes 157 62.30%	Underperform Votes 95 37.70%

Does the media prefer ACLX or GMAB?

In the previous week, Arcellx had 2 more articles in the media than Genmab A/S. MarketBeat recorded 7 mentions for Arcellx and 5 mentions for Genmab A/S. Arcellx's average media sentiment score of 1.18 beat Genmab A/S's score of 0.59 indicating that Arcellx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcellx	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, ACLX or GMAB?

Arcellx has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Summary

Genmab A/S beats Arcellx on 10 of the 19 factors compared between the two stocks.